Glucose-6-phosphate dehydrogenase

Where the papers sit

9 papers from the last 6 months study glucose-6-phosphate dehydrogenase directly · updated from PubMed 3 Oct 2026

• Redox Control of Chemoresistance

  Redox rewiring is being used to explain ferroptosis and treatment failure in cancer, especially pancreatic cancer. LZTFL1 amplifies ferroptosis through NADPH–glutathione metabolism, whereas cancer-associated fibroblast mitophagy rewires pyrimidine metabolism to fuel chemoresistance. Glycyrrhetinic acid and autocrine motility factor converge on G6PD suppression, oxidative stress and drug retention, with gemcitabine-relevant implications. The shared direction is toward targeting tumor–stroma metabolism rather than treating resistance as purely cell-intrinsic.

  3 papers · 33.3%

• Itaconate in Lung Cancer

  Itaconate is emerging as a metabolic link between macrophages and lung tumors. IRG1-derived itaconate and 4-octyl itaconate inhibit the PPP/G6PD axis, reshaping redox metabolism in both the tumor microenvironment and cancer cells. The work is moving toward manipulating this macrophage–tumor metabolic circuit as a lung-cancer strategy. Whether G6PD inhibition yields durable tumor control without disrupting protective immune functions remains open.

  2 papers · 22.2%

• Others — G6PD-Linked Oxidative Stress

  G6PD-linked oxidative stress appears in vascular disease and β-cell dysfunction, while separate work maps inhibitor binding. Ang II/high-salt aneurysm formation is reduced by G6PD inhibition, and a lncRNA–miR-24-3p–G6PD axis is implicated in type 1 diabetes. Primaquine and tafenoquine work instead addresses stakeholder perceptions of high-dose antimalarial safety. The cluster shares G6PD relevance but has no single biological or clinical direction.

  4 papers · 44.4%